Chiossone L, Dumas P-Y, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671–88.

Article  PubMed  Google Scholar 

Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19:120.

Article  PubMed  PubMed Central  Google Scholar 

Thomas M, Boname JM, Field S, Nejentsev S, Salio M, Cerundolo V, et al. Down-regulation of NKG2D and NKp80 ligands by Kaposi’s sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci. 2008;105:1656–61.

Article  PubMed  PubMed Central  Google Scholar 

Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken JB, Lardon F, et al. The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies. Front Immunol. 2021;12:737311.

Article  PubMed  PubMed Central  Google Scholar 

Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856–68.

Article  PubMed  Google Scholar 

Riggan L, Shah S, O’Sullivan TE. Arrested development: suppression of NK cell function in the tumor microenvironment. Clin Transl Immunol. 2021;10:e1238.

Article  Google Scholar 

Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557–75.

Article  PubMed  PubMed Central  Google Scholar 

Endoh H, Ishibashi Y, Yamaki E, Yoshida T, Yajima T, Kimura H, et al. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer. 2009;63:241–6.

Article  PubMed  Google Scholar 

Dominguez C, Tsang K-Y, Palena C. Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. Cell Death Dis. 2016;7:e2380–e.

Article  PubMed  PubMed Central  Google Scholar 

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136:331–45.

Article  PubMed  Google Scholar 

Hashmi AA, Naz S, Hashmi SK, Irfan M, Hussain ZF, Khan EY, et al. Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters. Surg Exp Pathol. 2019;2:81–90.

Google Scholar 

Lin S-Y, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3:802–8.

Article  PubMed  Google Scholar 

Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol. 1990;21:277–82.

Article  PubMed  Google Scholar 

Marti U, Ruchti C, Kämpf J, Thomas GA, Williams ED, Peter HJ, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid. 2001;11:137–45.

Article  PubMed  Google Scholar 

Lo H-W, Hsu S-C, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005;7:575–89.

Article  PubMed  Google Scholar 

Lo H-W, Xia W, Wei Y, Ali-Seyed M, Huang S-F, Hung M-C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65:338–48.

Article  PubMed  Google Scholar 

Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005;11:5856–62.

Article  PubMed  Google Scholar 

Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005;23:5323–33.

Article  PubMed  Google Scholar 

Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009;115:115–21.

Article  PubMed  Google Scholar 

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615–23.

Article  PubMed  PubMed Central  Google Scholar 

Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, Mccormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110:55–62.

Article  PubMed  Google Scholar 

Kim C, Liu SV. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Ann Oncol. 2019;30:1852–5.

Article  PubMed  Google Scholar 

Wang S-C, Hung M-C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 2009;15:6484–9.

Article  PubMed  PubMed Central  Google Scholar 

Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010;123:1716–23.

Article  PubMed  PubMed Central  Google Scholar 

Atwell B, Chen C-Y, Christofferson M, Montfort WR, Schroeder J. Sorting nexin-dependent therapeutic targeting of oncogenic epidermal growth factor receptor. Cancer Gene Ther. 2023;30:267–76.

Article  PubMed  Google Scholar 

Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 2009;15:100–9.

Article  PubMed  PubMed Central  Google Scholar 

Maisel SA, Schroeder J. Wrong place at the wrong time: how retrograde trafficking drives cancer metastasis through receptor mislocalization. J Cancer Metastasis Treatment. 2019;5:1–14.

Google Scholar 

Batista TM, Cederquist CT, Kahn CR. The insulin receptor goes nuclear. Cell Res. 2019;29:509–11.

Article  PubMed  PubMed Central  Google Scholar 

Giri DK, Ali-Seyed M, Li L-Y, Lee D-F, Ling P, Bartholomeusz G, et al. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol. 2005;25:11005–18.

Article  PubMed  PubMed Central  Google Scholar 

Maher PA. Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J cell Biol. 1996;134:529–36.

Article  PubMed  Google Scholar 

Reif R, Adawy A, Vartak N, Schröder J, Günther G, Ghallab A, et al. Activated ErbB3 translocates to the nucleus via clathrin-independent endocytosis, which is associated with proliferating cells. J Biol Chem. 2016;291:3837–47.

Article  PubMed  Google Scholar 

Liu S, Geng R, Lin E, Zhao P, Chen Y. ERBB1/2/3 expression, prognosis, and immune infiltration in cutaneous melanoma. Front Genet. 2021;12:602160.

Article  PubMed  PubMed Central  Google Scholar 

Makhijani P, Basso PJ, Chan YT, Chen N, Baechle J, Khan S, et al. Regulation of the immune system by the insulin receptor in health and disease. Front Endocrinol. 2023;14:1128622.

Article  Google Scholar 

Hart MR, Su H-Y, Broka D, Goverdhan A, Schroeder JA. Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression. Mol Ther. 2013;21:1996–2007.

Article  PubMed  PubMed Central  Google Scholar 

Hsu S-C, Hung M-C. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem. 2007;282:10432–40.

Article